KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to ...
Morningstar4d
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase ...
Business Wire12d
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following ...
Morningstar5d
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
Links to all posters and presentations shared at AAAAI can be found on the KalVista website under Publications. Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or ...
ETF Daily News18d
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Significant Drop in Short Interest
The firm has a market cap of $482.19 million, a PE ratio of -2.68 and a beta of 0.85. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The business ...
Yahoo Finance15d
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
CAMBRIDGE, Mass. & SALISBURY, England, February 21, 2025--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the ...
Investing5d
Sebetralstat shows promise in treating HAE attacks
CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shared new data at the AAAAI/WAO 2025 Joint Congress, indicating their investigational drug sebetralstat could ...
Yahoo Finance13d
KalVista Pharmaceuticals Inc. R (4XC1.BE)
CAMBRIDGE, Mass. & SALISBURY, England, February 21, 2025--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy ...